Embryonal tumors in the adult population: Implications in therapeutic planning

A. Boiardi, A. Silvani, M. Eoli, L. Fariselli, B. Zappacosta, A. Salmaggi

Research output: Contribution to journalArticle

Abstract

The natural history of neuroectodermal tumors is still debated as far as prognostic factors are concerned; the same uncertainty applies to the optimal radiotherapy schedule and even more to the presumptive additive effect of chemotherapy. The rarity of these tumors and the heterogeneity of management make interpretation of literature data also more difficult. We evaluated clinical course in a cohort of 39 patients, including 31 with medulloblastoma (MB) and 8 with primitive neuroectodermal tumors (PNET). All patients were treated with radiotherapy, a standardized chemotherapy protocol including PCV scheme, and a second-line chemotherapy with cisplatin and etoposide (VP16) at recurrence. In 27 patients, intrathecal chemotherapy was also delivered. Median follow-up was 10.8 years. Overall, PNET had a worse outcome as compared to MB: median survival times were 42.8 vs. 92.6 months, respectively (p = 0.05). At 5 years, 45% of MB patients are alive. No significant difference in disease-free period was found between patients of different age, desmoplastic variant, tumor localization, or extent of surgery. Patients considered to be 'high risk' had a significantly shorter disease-free period as compared with low-risk patients (27 vs. 54.7 months, p = 0.04). Systemic or intrathecal chemotherapy did not influence progression-free survival (PFS). However, in the majority of chemotherapy-treated patients, a low-dose craniospinal radiotherapy was also delivered. This combination of treatments may have avoided the expected increased percentage of failure. Moreover, more than half of recurrent patients had a partial response to chemotherapy that extended survival for approximately 3 years. Repeated surgery and chemotherapy at recurrence favorably influenced survival time.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalNeurological Sciences
Volume21
Issue number1
DOIs
Publication statusPublished - 2000

Fingerprint

Drug Therapy
Population
Neoplasms
Medulloblastoma
Primitive Neuroectodermal Tumors
Radiotherapy
Therapeutics
Survival
Neuroectodermal Tumors
Recurrence
Etoposide
Cisplatin
Disease-Free Survival
Uncertainty
Appointments and Schedules

Keywords

  • Chemotherapy
  • Medulloblastoma
  • PNET
  • Prognostic factors
  • Radiotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Embryonal tumors in the adult population : Implications in therapeutic planning. / Boiardi, A.; Silvani, A.; Eoli, M.; Fariselli, L.; Zappacosta, B.; Salmaggi, A.

In: Neurological Sciences, Vol. 21, No. 1, 2000, p. 23-30.

Research output: Contribution to journalArticle

@article{84e11ce18db24f3f939cd49f530ebcf7,
title = "Embryonal tumors in the adult population: Implications in therapeutic planning",
abstract = "The natural history of neuroectodermal tumors is still debated as far as prognostic factors are concerned; the same uncertainty applies to the optimal radiotherapy schedule and even more to the presumptive additive effect of chemotherapy. The rarity of these tumors and the heterogeneity of management make interpretation of literature data also more difficult. We evaluated clinical course in a cohort of 39 patients, including 31 with medulloblastoma (MB) and 8 with primitive neuroectodermal tumors (PNET). All patients were treated with radiotherapy, a standardized chemotherapy protocol including PCV scheme, and a second-line chemotherapy with cisplatin and etoposide (VP16) at recurrence. In 27 patients, intrathecal chemotherapy was also delivered. Median follow-up was 10.8 years. Overall, PNET had a worse outcome as compared to MB: median survival times were 42.8 vs. 92.6 months, respectively (p = 0.05). At 5 years, 45{\%} of MB patients are alive. No significant difference in disease-free period was found between patients of different age, desmoplastic variant, tumor localization, or extent of surgery. Patients considered to be 'high risk' had a significantly shorter disease-free period as compared with low-risk patients (27 vs. 54.7 months, p = 0.04). Systemic or intrathecal chemotherapy did not influence progression-free survival (PFS). However, in the majority of chemotherapy-treated patients, a low-dose craniospinal radiotherapy was also delivered. This combination of treatments may have avoided the expected increased percentage of failure. Moreover, more than half of recurrent patients had a partial response to chemotherapy that extended survival for approximately 3 years. Repeated surgery and chemotherapy at recurrence favorably influenced survival time.",
keywords = "Chemotherapy, Medulloblastoma, PNET, Prognostic factors, Radiotherapy",
author = "A. Boiardi and A. Silvani and M. Eoli and L. Fariselli and B. Zappacosta and A. Salmaggi",
year = "2000",
doi = "10.1007/s100720070115",
language = "English",
volume = "21",
pages = "23--30",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Embryonal tumors in the adult population

T2 - Implications in therapeutic planning

AU - Boiardi, A.

AU - Silvani, A.

AU - Eoli, M.

AU - Fariselli, L.

AU - Zappacosta, B.

AU - Salmaggi, A.

PY - 2000

Y1 - 2000

N2 - The natural history of neuroectodermal tumors is still debated as far as prognostic factors are concerned; the same uncertainty applies to the optimal radiotherapy schedule and even more to the presumptive additive effect of chemotherapy. The rarity of these tumors and the heterogeneity of management make interpretation of literature data also more difficult. We evaluated clinical course in a cohort of 39 patients, including 31 with medulloblastoma (MB) and 8 with primitive neuroectodermal tumors (PNET). All patients were treated with radiotherapy, a standardized chemotherapy protocol including PCV scheme, and a second-line chemotherapy with cisplatin and etoposide (VP16) at recurrence. In 27 patients, intrathecal chemotherapy was also delivered. Median follow-up was 10.8 years. Overall, PNET had a worse outcome as compared to MB: median survival times were 42.8 vs. 92.6 months, respectively (p = 0.05). At 5 years, 45% of MB patients are alive. No significant difference in disease-free period was found between patients of different age, desmoplastic variant, tumor localization, or extent of surgery. Patients considered to be 'high risk' had a significantly shorter disease-free period as compared with low-risk patients (27 vs. 54.7 months, p = 0.04). Systemic or intrathecal chemotherapy did not influence progression-free survival (PFS). However, in the majority of chemotherapy-treated patients, a low-dose craniospinal radiotherapy was also delivered. This combination of treatments may have avoided the expected increased percentage of failure. Moreover, more than half of recurrent patients had a partial response to chemotherapy that extended survival for approximately 3 years. Repeated surgery and chemotherapy at recurrence favorably influenced survival time.

AB - The natural history of neuroectodermal tumors is still debated as far as prognostic factors are concerned; the same uncertainty applies to the optimal radiotherapy schedule and even more to the presumptive additive effect of chemotherapy. The rarity of these tumors and the heterogeneity of management make interpretation of literature data also more difficult. We evaluated clinical course in a cohort of 39 patients, including 31 with medulloblastoma (MB) and 8 with primitive neuroectodermal tumors (PNET). All patients were treated with radiotherapy, a standardized chemotherapy protocol including PCV scheme, and a second-line chemotherapy with cisplatin and etoposide (VP16) at recurrence. In 27 patients, intrathecal chemotherapy was also delivered. Median follow-up was 10.8 years. Overall, PNET had a worse outcome as compared to MB: median survival times were 42.8 vs. 92.6 months, respectively (p = 0.05). At 5 years, 45% of MB patients are alive. No significant difference in disease-free period was found between patients of different age, desmoplastic variant, tumor localization, or extent of surgery. Patients considered to be 'high risk' had a significantly shorter disease-free period as compared with low-risk patients (27 vs. 54.7 months, p = 0.04). Systemic or intrathecal chemotherapy did not influence progression-free survival (PFS). However, in the majority of chemotherapy-treated patients, a low-dose craniospinal radiotherapy was also delivered. This combination of treatments may have avoided the expected increased percentage of failure. Moreover, more than half of recurrent patients had a partial response to chemotherapy that extended survival for approximately 3 years. Repeated surgery and chemotherapy at recurrence favorably influenced survival time.

KW - Chemotherapy

KW - Medulloblastoma

KW - PNET

KW - Prognostic factors

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033933287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033933287&partnerID=8YFLogxK

U2 - 10.1007/s100720070115

DO - 10.1007/s100720070115

M3 - Article

C2 - 10938199

AN - SCOPUS:0033933287

VL - 21

SP - 23

EP - 30

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 1

ER -